These results suggest that CJE could activate the phosphorylation of the IRS1-PI3K-Akt pathway and inhibit the phosphorylation of FoxO1/GSK-3β to promote hepatic gluconeogenesis and glycogen synthesis, thus alleviating glucose metabolism disruptions and insulin resistance in T2DM mice. The gene discussed is FOXO1; the disease is type 2 diabetes mellitus.